Medicine
Lytgobi 4 mg tablet
Lytgobi 4 mg tablet is a prescription medicine containing Futibatinib for oral use, marketed by Taiho Pharmaceutical, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store LYTGOBI tablets at room temperature 20°C to 25°C (68°F to 77°F)…
Key facts
- Active ingredient (INN)
- Futibatinib
- Brand
- Lytgobi
- Strength
- 4 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 blister pack
- Marketing authorisation holder
- Taiho Pharmaceutical
- Manufacturer
- Taiho Pharmaceutical
- Origin register
- US FDA, United States
- Storage
- Store LYTGOBI tablets at room temperature 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F to 86°F). ().
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01EN04 Futibatinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 February 2023
- Identifiers
- DailyMed set ID 0b1332a1-0581-4707-9bf6-1eccfa39bef4NDC 64842-0120Application NDA214801
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 blister pack in 1 carton / 21 tablet in 1 blister pack | 64842-0120-4 | Taiho Pharmaceutical | 3 February 2023 |
| 1 blister pack in 1 carton / 28 tablet in 1 blister pack | 64842-0120-5 | Taiho Pharmaceutical | 3 February 2023 |
| 1 blister pack in 1 carton / 35 tablet in 1 blister pack | 64842-0120-6 | Taiho Pharmaceutical | 3 February 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Futibatinib is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. MedsAcross supplies Futibatinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about FutibatinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- LYTGOBI prescribing information (Taiho Pharmaceutical) · U.S. National Library of Medicine, DailyMed
- Lytgobi: European public assessment report (EPAR) · European Medicines Agency
Need Lytgobi 4 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.